ViroPharma Announces Key Additions to European Management

EXTON, Pennsylvania, July 10 /PRNewswire/ --

ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company
has added two key members of management to its European subsidiary,
ViroPharma Europe.

Thierry Darcis, MD, MBA, joins ViroPharma as vice president, general
manager, ViroPharma Europe. Dr. Darcis will be responsible for the general
management of ViroPharma Europe; for the development of commercial strategies
for Europe with a special focus on UK, Germany, France, Spain, and Italy; and
to ensure commercial excellence in all areas, including pricing and
reimbursement strategies, and sales. He joins the company after serving as
vice president, global marketing head and member of the executive team at
Novartis Vaccines.

Richard Bax, MBBS, FRCP, MRCGP, FFMP joins ViroPharma as vice president,
clinical development and medical affairs, ViroPharma Europe. Dr. Bax will be
responsible for the development of the European clinical and medical affairs
activities and infrastructure, and for European clinical strategies for
CAMVIA(TM) (maribavir); he will also be involved in identifying and assessing
new European business development opportunities. He joins the company from
his most recent posts as a consultant focused on developing clinical and
regulatory strategies; and as vice president, clinical development, Europe
for Chiron Corporation.

"Thierry and Richard bring to ViroPharma a depth of knowledge and
experience that we believe will be instrumental in building our European
presence as we begin our ex-US development and commercialization work for
CAMVIA, and in leveraging the organization to other business endeavors,"
commented Daniel Soland, ViroPharma's chief commercial officer. "Their
experiences at Novartis Vaccines and GSK Biologicals, and at Chiron and
SmithKline Beecham, respectively, will be integral parts in the development
of ViroPharma Europe. We are extremely pleased to be able to attract such
highly qualified individuals to ViroPharma, and we all look forward to
working closely with them. "

As vice president of global marketing for Novartis Vaccines, Dr. Darcis
was responsible for the global marketing function. Most recently, he was
involved in the launch and life cycle management of products including
Fluad(R) (MF59-adjuvanted influenza vaccine) and Optaflu(R), the first cell
culture-derived influenza vaccine. Prior to Novartis Vaccines, Dr. Darcis
spent over five years with GlaxoSmithKline Biologicals in Rixensart, Belgium,
culminating in his tenure as head of marketing excellence, with
responsibility for rolling out the 'GSK Brand and Market Building' process
piloted with the Infanrix(R) (Diphtheria and Tetanus Toxoids and Acellular
Pertussis Vaccine Adsorbed) product range. He previously acted as the head of
GSK Biologicals' commercial pediatric team. Before GSK Biologicals, he worked
for UCB Pharma, and as a physician at the Cape Town City Council Health Care
department and Tygerberg Hospital in Capetown, South Africa and H.F. Verwoerd
Hospital in Pretoria, South Africa. Dr. Darcis received his medical degree
from the Catholic University of Leuven, Belgium; his masters of business
administration from the University of Stellenbosch, South Africa; and his
degree in marketing and advertising from the Solvay Business School in
Brussels.

As a consultant, Dr. Bax worked with clients including Schroeders
venture capital group and the Gates Foundation. At Chiron Corporation, Dr. 
Bax' served as vice president, clinical development, Europe, and achieved 
successful European registrations for products including Cubicin(R) 
(daptomycin) and Cardioxane(R) (dexrazoxane). Prior to his tenure at Chiron
Corporation, he was the chief scientific officer for Biosyn Inc., a
Philadelphia-based specialty pharmaceutical company. Dr. Bax spent nine years
with SmithKline Beecham as vice president and global director of the
anti-infective clinical research and development therapeutic unit, where he
developed, licensed and launched products including Famciclovir and
Augmentin(R) (amoxicillin/clavulanate potassium) BID. In previous roles in
the pharmaceutical industry, Dr. Bax has been instrumental in the development
and approval of numerous anti-infectives, including meropenem, moxalactam,
cefotetan, and cefuroxime. Dr. Bax is the author of over 100 scientific
publications on pharmaceutical development, antibiotic discovery, and
bacterial resistance and is on the central advisory committee of the
International Partnership on Microbicides. He received his bachelor of
medicine and bachelor of surgery (MBBS) from the Royal Free Hospital School
of Medicine, University of London, and is a Fellow of the Royal College of
Physicians (FRCP) in London and Edinburgh.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and
commercialization of products that address serious diseases treated by
physician specialists and in hospital settings. ViroPharma commercializes
Vancocin(R) approved for oral administration for treatment of
antibiotic-associated pseudomembranous colitis caused by Clostridium
difficile and enterocolitis caused by Staphylococcus aureus, including
methicillin-resistant strains (for prescribing information, please download
the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm).
ViroPharma currently focuses its drug development activities in viral
diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more
information on ViroPharma, visit the Company's website at
http://www.viropharma.com.

Web site: http://www.viropharma.com
              http://www.viropharma.com/docs/Vancocin_pi_2007.htm